Is Alphabet Stock No Longer a Good Bet?
Alphabet tripled its price per share over the past 5…
Sell
46
CLB Quote, Financials, Valuation and Earnings
Last price:
$15.39
Seasonality move
:
11.76%
Day range:
$14.92 - $15.30
52-week range:
$12.95 - $25.13
Dividend yield:
0.26%
P/E ratio:
23.02x
P/S ratio:
1.38x
P/B ratio:
2.82x
Volume:
310.2K
Avg. volume:
368.7K
1-year change:
-5.48%
Market cap:
$711.3M
Revenue:
$523.8M
EPS (TTM):
$0.66
Analysts' Opinion
-
Consensus RatingCore Laboratories has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $18.50, Core Laboratories has an estimated upside of 21.79% from its current price of $15.19.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $13.00 representing 100% downside risk from its current price of $15.19.
Fair Value
-
According to the consensus of 4 analysts, Core Laboratories has 21.79% upside to fair value with a price target of $18.50 per share.
CLB vs. S&P 500
-
Over the past 5 trading days, Core Laboratories has overperformed the S&P 500 by 2.51% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Core Laboratories does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Core Laboratories has grown year-over-year revenues for 5 quarters straight. In the most recent quarter Core Laboratories reported revenues of $129.2M.
Earnings Growth
-
Core Laboratories has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Core Laboratories reported earnings per share of $0.15.
Enterprise value:
824M
EV / Invested capital:
2.15x
Price / LTM sales:
1.38x
EV / EBIT:
14.07x
EV / Revenue:
1.57x
PEG ratio (5yr expected):
0.36x
EV / Free cash flow:
19.00x
Price / Operating cash flow:
16.72x
Enterprise value / EBITDA:
11.21x
Gross Profit (TTM):
$88.4M
Return On Assets:
5.3%
Net Income Margin (TTM):
5.99%
Return On Equity:
12.8%
Return On Invested Capital:
7.99%
Operating Margin:
8.19%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $489.7M | $509.8M | $523.8M | $128.2M | $129.2M | |
| Gross Profit | $78.9M | $94M | $88.4M | $22.8M | $19.4M | |
| Operating Income | $37.9M | $54.8M | $49.5M | $14.5M | $10.6M | |
| EBITDA | $58.7M | $70.4M | $73.5M | $18.5M | $17.8M | |
| Diluted EPS | $0.41 | $0.76 | $0.66 | $0.04 | $0.15 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $165.8M | $189.1M | $211.7M | $223.1M | $226.6M | |
| Total Assets | $568.6M | $580.9M | $578.4M | $586.4M | $590.4M | |
| Current Liabilities | $89.8M | $90.8M | $103.1M | $88.1M | $97.6M | |
| Total Liabilities | $493M | $419.9M | $389.4M | $356.6M | $332.7M | |
| Total Equity | $75.6M | $161M | $189M | $229.8M | $257.7M | |
| Total Debt | $259.4M | $188.6M | $172.4M | $163.1M | $126.1M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $25M | $24.8M | $56.4M | $19.4M | $20.6M | |
| Cash From Investing | -$3.9M | -$6.7M | -$6.4M | -$2.4M | -$3.6M | |
| Cash From Financing | -$23.4M | -$18.4M | -$46M | -$18.5M | -$19.4M | |
| Free Cash Flow | $14.7M | $14.2M | $43.4M | $16.9M | $16.2M | |
CLB
Sector
Market Cap
$711.3M
$59.2M
Price % of 52-Week High
60.45%
59.47%
Dividend Yield
0.26%
0%
Shareholder Yield
2.16%
4.67%
1-Year Price Total Return
-5.48%
-22.79%
Beta (5-Year)
2.382
1.027
Dividend yield:
0.26%
Annualized payout:
$0.04
Payout ratio:
5.98%
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$14.83
200-day SMA
Sell
Level
$18.91
Bollinger Bands (100)
Sell
Level
16.24 - 20.18
Chaikin Money Flow
Buy
Level
20.5M
20-day SMA
Sell
Level
$15.30
Relative Strength Index (RSI14)
Sell
Level
46.05
ADX Line
Sell
Level
26.61
Williams %R
Sell
Level
-12.8405
50-day SMA
Sell
Level
$17.05
MACD (12, 26)
Sell
Level
-0.65
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Sell
Level
-3.5M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.2951)
Buy
CA Score
(Annual)
Level (-0.1023)
Buy
Beneish M-Score
(Annual)
Level (-2.5557)
Buy
Momentum Score
Level (7)
Sell
Ohlson Score
Level (0.6075)
Buy
Piotroski F Score
(Annual)
Level (6)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (6)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Core Laboratories Inc provides reservoir description and production enhancement services for oil and gas exploration and production. It provides data and analytics to aid well operators in determining optimal methods for recovering, processing, and refining hydrocarbons from a well. It also manufactures the associated lab equipment for its services.
Stock Forecast FAQ
In the current month, CLB has received 0 Buy ratings 4 Hold ratings, and 0 Sell ratings. The CLB average analyst price target in the past 3 months is $18.50.
-
Where Will Core Laboratories Stock Be In 1 Year?
According to analysts, the consensus estimate is that Core Laboratories share price will rise to $18.50 per share over the next 12 months.
-
What Do Analysts Say About Core Laboratories?
Analysts are divided on their view about Core Laboratories share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Core Laboratories is a Sell and believe this share price will drop from its current level to $13.00.
-
What Is Core Laboratories's Price Target?
The price target for Core Laboratories over the next 1-year time period is forecast to be $18.50 according to 4 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is CLB A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Core Laboratories is a Hold. 4 of 4 analysts rate the stock a Hold at this time.
-
How Can I Buy Shares Of CLB?
You can purchase shares of Core Laboratories via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Core Laboratories shares.
-
What Is The Core Laboratories Share Price Today?
Core Laboratories was last trading at $15.39 per share. This represents the most recent stock quote for Core Laboratories. Yesterday, Core Laboratories closed at $15.19 per share.
-
How To Buy Core Laboratories Stock Online?
In order to purchase Core Laboratories stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Pepsi Vs Coke Stock: Which Is Best?
Coca-Cola (NYSE:KO) and PepsiCo (NYSE:PEP) are two of the largest…
Is CyberArk The Next Big Cybersecurity Stock?
CyberArk Software (NASDAQ: CYBR) recently reported phenomenal quarter numbers, passing…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Sell
48
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
51
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Buy
52
RGC alert for Mar 19
Regencell Bioscience Holdings [RGC] is down 0.66% over the past day.
Sell
49
SRPT alert for Mar 19
Sarepta Therapeutics [SRPT] is up 8.72% over the past day.
Sell
46
CVNA alert for Mar 19
Carvana [CVNA] is up 5.74% over the past day.
